Objective: To evaluate major bleeding risk factors in percutaneous nephrolithotomy (PCNL) for upper urinary tract calculi and validate a prediction model.
Study Design: Analytical study. Place and Duration of the Study: The First Affiliated Hospital of Wannan Medical College, Wuhu, China, from January 2019 to August 2023.
Methodology: Major bleeding was defined as a decrease in haemoglobin of ≥20 g/L compared to preoperative levels. A retrospective analysis of 468 PCNL patients identified risk factors for major bleeding using univariate, LASSO, and logistic regression analyses. Nomogram models were developed using R software, with ROC and calibration plots assessing the model's accuracy. The bootstrap method provided internal validation, and DCA evaluated clinical utility.
Results: Independent risk factors included diabetes (OR = 4.17), staghorn calculi (OR = 3.41), operative duration (OR = 1.01), and staged surgery (OR = 2.75). The model showed high discriminative ability (C-statistic: 0.783) and alignment with observed outcomes. Internal validation confirmed robustness (C-statistic: 0.728).
Conclusion: The predictive model for major bleeding during and after PCNL, focusing on diabetes, staghorn calculi, operative duration, and staged surgery, is highly accurate, aiding in the PCNL risk assessment.
Key Words: Upper urinary tract calculi, Percutaneous nephrolithotomy, Major bleeding, Risk factors, Prediction model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.29271/jcpsp.2024.12.1478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clazosentan's dual edge in managing vasospasm following aneurysmal subarachnoid hemorrhage: an updated systematic review, meta-analysis, and meta-regression of clinical outcomes and safety profiles.
Neurosurg Rev
January 2025
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Aneurysmal Subarachnoid Hemorrhage (aSAH), resulting from ruptured aneurysms, is a major contributor to stroke-related mortality and morbidity. Despite advances in healthcare, aSAH remains severe and often leads to complications such as cerebral vasospasm (CV), cerebral infarction, and delayed ischemic neurological deficits (DIND). Clazosentan, an endothelin receptor antagonist, has demonstrated potential in alleviating vasospasm and its associated outcomes, although evidence of its efficacy remains unclear.
View Article and Find Full Text PDFTransvenous embolization of brain arteriovenous malformations featuring multiple draining veins with 4D-DSA: a case series and technical insights.
J Neurointerv Surg
January 2025
Intervention Neuroradiology, CHU Limoges, Limoges, Aquitaine-Limousin-Poitou-Charentes, France
Background: Hemorrhage is a major complication of brain arteriovenous malformations (AVMs) embolization, which can be related to persistent arteriovenous shunts that were not completely occluded during the embolization. In transvenous embolization (TVE) this risk is deemed higher for AVMs larger than 3 cm featuring multiple veins of drainage. Herein, we will discuss a few selected cases where brain AVMs with more than one draining vein were deemed safe for curative embolization with advanced endovascular techniques after a careful anatomical study through the four dimensional-digital subtraction angiography (4D-DSA) imaging.
View Article and Find Full Text PDFImpact of acetylsalicylic acid on perioperative bleeding complications in deceased donor kidney transplantation.
World J Urol
January 2025
Department of Urology, Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Purpose: The objective of this study was to evaluate the perioperative outcomes and complications associated with the use of acetylsalicylic acid (ASA) in deceased donor kidney transplantation (KTX), with a particular focus on bleeding events.
Methods: We retrospectively analyzed 157 kidney transplant recipients (KTRs) who underwent KTX at Charité Berlin, Department for Urology, between February 2014 and December 2017. Patients were divided into two groups: patients with ASA in their preoperative medication (Group A, n = 59) and patients without ASA use (Group B, n = 98).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Stark Neurosciences Research Institute, Department of Neurology, Indianapolis, IN, USA.
Anti-amyloid immunotherapy holds great promise for our patients and their families as the first disease-modifying therapy for the treatment of Alzheimer's disease (AD) to be approved. Positive clinical trials for lecanamab and donanemab showed significant and rapid lowering of brain amyloid burden and a significant slowing of cognitive decline. Amyloid-related imaging abnormalities (ARIA) in the form of vasogenic edema (ARIA-E) and micro - and macro- hemorrhages (ARIA-H) remain the major obstacle to broad use of these agents.
View Article and Find Full Text PDFEnhancing Recovery in Severe Adolescent Idiopathic Scoliosis (AIS) Patients With Cobb Angle ≥90 Degrees Undergoing Single-staged Posterior Spinal Fusion (PSF): Evaluating the Feasibility of Rapid Recovery Protocol (RRP).
Clin Spine Surg
January 2025
Department of Orthopaedic Surgery, National Orthopaedic Centre of Excellence for Research and Learning (NOCERAL), Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Study Design: Retrospective study.
Objective: To assess the feasibility and outcome of rapid recovery protocol (RRP) in severe adolescent idiopathic scoliosis (AIS) patients with Cobb angle ≥90 degrees underwent single-staged posterior spinal fusion (PSF).
Summary Of Background Data: Corrective surgeries in severe AIS patients entail a higher risk of prolonged operation, excessive bleeding, extended hospital stay, and higher complication rates compared with non-severe AIS patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!